
Oldest-known ant preserved in 113 million-year-old Brazilian fossil
April 25 (Reuters) - Scientists have identified the fossilized remains of the oldest-known ant - a winged insect with fearsome scythe-like jaws that lived about 113 million years ago during the age of dinosaurs and was preserved in limestone unearthed in northeastern Brazil.
The species, called Vulcanidris cratensis, is part of a lineage called hell ants - named for their demonic-looking jaws - that prospered in a wide geographical range during the Cretaceous Period but have no descendants alive today. A previously discovered Cretaceous hell ant was named Haidomyrmex in honor of Hades, the ancient Greek god of the underworld.
here.
A medium-sized ant about a half-inch (1.35 cm) long, Vulcanidris possessed highly specialized jaws that would have enabled it to pin down or impale prey. Like some ants alive today, it had wings and appears to have been a capable flier. It also had a well-developed stinger like a wasp.
"It would probably be confused with a wasp by an untrained eye," said entomologist Anderson Lepeco of the Museum of Zoology of the University of São Paulo, lead author of the study published this week in the journal Current Biology, opens new tab.
"They probably used their mandibles (mouthparts) to handle their prey in a specific way," Lepeco said.
Its mandibles moved up and down and not side to side, as they do in today's ants.
"Currently, many odd mandible shapes can be found in ants, but they usually articulate horizontally," Lepeco said.
This ant is roughly 13 million years older than the previous oldest-known ants, specimens found in France and Myanmar that were preserved in amber, which is fossilized tree sap.
The Vulcanidris anatomy is remarkably well preserved in the limestone, which was excavated decades ago in the Crato geological formation in the Brazilian state of Ceará, probably in the 1980s or 1990s, according to Lepeco. It was held in a private collection before being donated to the São Paulo museum about five years ago.
"I was looking for wasps among the fossils of the collection and was shocked when I recognized this one as a close relative of a hell ant previously described from Burmese amber," Lepeco said, referring to the fossil from Myanmar.
The specialized nature of the Vulcanidris anatomy and the fact that two hell ants lived so far from each other during this part of the Cretaceous suggest that ants as a group emerged many millions of years before this newly identified species existed.
"According to molecular estimates, ants originated between 168 million and 120 million years ago. This new finding supports an earlier age within these limits," Lepeco said.
Ants are believed to have evolved from a form of wasp. Their closest living relatives are wasps and bees.
Vulcanidris inhabited an ecosystem teeming with life. Fossils from the region show that Vulcanidris lived alongside other insects, spiders, millipedes, centipedes, various crustaceans, turtles, crocodilians, flying reptiles called pterosaurs, birds and dinosaurs including the feathered meat-eater Ubirajara. The ant's predators may have included frogs, birds, spiders and larger insects.
Ants have colonized almost everywhere on Earth, and research published in 2022 estimated that their total population is 20 quadrillion globally. That dwarfs the human population of about 8 billion.
"They are one of the most abundant groups in most environments on Earth," Lepeco said.
"They play many roles where they occur, such as predation and herbivory, controlling populations of other organisms. They also have intrinsic relationships with specific plants and insects, protecting them from other animals. Subterranean and litter ants help in soil health, and they may also act as decomposers, feeding on dead organisms," Lepeco said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
a day ago
- Reuters
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
June 6 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.) Adding Roche's (ROG.S), opens new tab immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death compared to chemotherapy alone, according to trial data presented at recent medical meeting. Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15% of colon cancer patients have dMMR tumors, which do not respond well to chemotherapy. "The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer," study leader Dr. Frank Sinicrope of the Mayo Clinic in Rochester, Minnesota said in a statement. The data, opens new tab were presented at the ASCO meeting that concluded earlier this week. The trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. Half of the study participants received chemotherapy along with Tecentriq, which activates the immune system to attack and kill cancer cells, for six months, followed by the immunotherapy alone for another six months. The other half of the patients received chemotherapy for 12 months. The benefit of Tecentriq was seen even in the oldest patients and those at particularly high-risk. "It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival," Sinicrope said. As patients recover after a minimally invasive heart procedure, they might be better off continuing to take a certain type of blood-thinning drug to help prevent a heart attack or stroke, instead of continuing with the traditional aspirin, a new study suggests. Early after percutaneous coronary intervention (PCI) - a procedure to prop open blocked arteries either after a heart attack, or to prevent one - patients often receive dual anti-clotting therapy with both a P2Y12 inhibitor such as clopidogrel, the generic version of Plavix, or AstraZeneca's (AZN.L), opens new tab Brilinta (ticagrelor), and aspirin. After several months, patients are usually switched from dual therapy to lifelong daily aspirin use. But pooled data looking at patients who took part in five earlier clinical trials found that continuing to prescribe the P2Y12 inhibitors and stopping the aspirin was associated with lower rates of death, heart attack and stroke compared with continuing the aspirin, with no increased risk of major bleeding, researchers reported in The BMJ, opens new tab. Overall, the trials involved 16,117 patients who received either a P2Y12 inhibitor or aspirin after completing dual therapy following PCI. After an average follow-up period of around 4 years, P2Y12 inhibitor therapy was associated with a 23% lower risk of a composite of heart-related death, heart attack, or stroke, compared with aspirin, with no significant difference in major bleeding. That translates into one prevented cardiovascular death, heart attack, or stroke for every 46 patients taking a P2Y12 inhibitor instead of aspirin after dual therapy. Overall, the findings suggest that P2Y12 inhibitor drugs should be preferred over aspirin 'due to reductions in major adverse cardiac and cerebrovascular events without increasing major bleeding in the medium term,' according to an editorial published with the study. But the editorial said that since patients are advised to continue the post-PCI therapy for life, large trials directly comparing the different strategies with longer follow up are needed. Some diabetes and weight-loss drugs from the class known as GLP-1 agonists were linked with a small but elevated risk for an age-related eye disease in patients with diabetes, according to a study published on Thursday in JAMA Ophthalmology, opens new tab. In 139,000 patients with diabetes, including 46,334 who had been using the GLP-1 drugs semaglutide or lixisenatide, researchers identified 181 new cases of neovascular age-related macular degeneration, also known as wet AMD. Wet AMD is a degenerative eye disease marked by the abnormal growth of blood vessels under the retina that leak fluid or blood and can lead to blindness. The risk of developing AMD during up to three years of follow-up was low, at 0.2% in GLP-1 users versus 0.1% in non-users. Still, the researchers point out, after accounting for patients' individual risk factors, the odds of AMD were doubled with at least six months of GLP-1 use and tripled in patients with the longest duration of use. Semaglutide is the active ingredient in the widely used Novo Nordisk ( opens new tab drugs Ozempic and Wegovy, while lixisenatide is the main ingredient in Sanofi's ( opens new tab discontinued Adlyxin. GLP-1 drugs have also been associated with higher risks for an eye condition known as nonarteritic anterior ischemic optic neuropathy, or NAION. Researchers did not have information about the dose, route of administration, or frequency of administration of the medications used in the study. Even with that information, the study could not have proved cause and effect. At least one earlier study with longer follow up reported that GLP-1 use was linked with a lower, rather than higher, risk for AMD. 'Our findings are not directly contradictory' with that earlier report, said study leader Dr. Reut Shor of the University of Toronto. 'Factors such as timing and duration of exposure, disease stage, and patient characteristics may all influence outcomes," Shor said. "Our results add another layer to the emerging understanding of this complex relationship and emphasize the need for further research to clarify these trends.' (To receive the full newsletter in your inbox for free sign up here)


Reuters
2 days ago
- Reuters
Artificial Intelligence is now an A+ law student, study finds
June 5 (Reuters) - The latest generation of generative artificial intelligence can ace most law school final exams, a new study has found. OpenAI's newest model, called o3, earned grades ranging from A+ to B on eight spring finals given by faculty at the University of Maryland Francis King Carey School of Law, researchers found in a new paper published on SSRN, opens new tab. Those high grades represent a significant improvement from previous studies done on earlier versions of ChatGPT, also from OpenAI, which scored B's, C's, and even one D's when researchers had them take law school finals in 2022 and 2023, according to the paper. Studies conducted earlier by other researchers had also found that ChatGPT earned 'mediocre' grades on law school finals and that although it improved the speed of legal writing, it did not improve the quality. Researchers also have found that AI can pass the bar exam. However, generative AI looks to be catching up to actual high-performing law students, based on the latest study. Unlike ChatGPT, which immediately generates text in response to a user's query, o3 is what is known as a reasoning model. This means that it generates tentative answers and multiple approaches to questions after internally evaluating and revising those responses, after which it produces the final text for the user. The study's authors — seven law professors from University of Maryland — graded the final answers from o3 on the same curve they use for their students. The program's answers earned an A+ in Constitutional Law, Professional Responsibility, and Property. Its answers got an A in Income Taxation, and an A- in Criminal Procedure. It scored a B+ in Secured Transactions and Torts, and a B in Administrative Law. The's answers program did well on both multiple choice questions and essays, the study found. However, there were some limitations on o3's answers. The program's relatively low grade in administrative law was attributable to the fact that o3 did not know about the 2024 U.S. Supreme Court opinion in Loper Bright Enterprises v. Raimondo, which overturned the Chevron doctrine, which was central to administrative law. That ruling had come shortly after the o3's knowledge cutoff date. The o3 program performed worse on one final when given access to the professor's notes — an unanticipated outcome the researchers attributed to the program being 'distracted' by too much text. OpenAI did not immediately respond to a request for comment on Thursday about the study's findings. The study's authors wrote that they are already contemplating an updated experiment to determine how much of a cheating threat AI poses by instructing the program to make occasional spelling and grammar mistakes, so that those exams will be difficult to distinguish from those completed by real students. Read more: ChatGPT passes law school exams despite 'mediocre' performance AI improves legal writing speed, not quality - study


Glasgow Times
2 days ago
- Glasgow Times
Michael Mosley's family reflect on one year since TV doctor's death
Mosley, who died aged 67 while on holiday with his wife Dr Clare Bailey Mosley on the Greek island of Symi last year, was known for popularising diets and fronting science programmes. His wife wrote on Instagram: 'It's hard to believe that a year has passed since we lost Michael. Not a day goes by without thinking of him – his warmth, his laughter, his endless curiosity about the world, and his deep love for our family. 'This past year has been the hardest of our lives. Navigating the loss of someone so central to our hearts and our home has changed everything. We have missed him in the big moments and the small ones. But we have also felt incredibly supported. 'The outpouring of love, stories and memories from so many of you has meant more than we can ever say. We have taken real comfort in knowing just how many lives Michael touched – not only through his work, but through his kindness, humour, and deep desire to help people live well for longer.' The message thanked 'everyone who has reached out, shared their grief, and carried us with their compassion, thank you. Your messages, letters and acts of remembrance have helped us through the darkest days.' It continued: 'We are trying, as a family to look forward. To carry on the work Michael was so passionate about. To live with purpose and joy, as he would have wanted us to.' 'With love and deepest gratitude, Clare and the Mosley family.' Last month, the family set up a research project to honour his memory, announcing that a new clinical research fellowship will be established in partnership with King's College London and the Chronic Disease Research Foundation (CDRF) to help improve the nation's metabolic health. The Mosleys have been working with King's College London and the CDRF, who will administer the Michael Mosley Memorial Research Fund, to appoint a dedicated research scientist. Mosley, known for fronting BBC and Channel 4 documentaries on health and diet, popularised the 5:2 diet, a form of intermittent fasting, through his book The Fast Diet. Michael Mosley died in 2024 (BBC/PA) His son Dr Jack Mosley, a GP registrar, who researched GLP-1 drug brands including Ozempic, Wegovy, Mounjaro and Zepbound with his father, has also written a book titled Food Noise: How Weight Loss Medication And Smart Nutrition Can Silence Your Cravings. In December, a coroner said Mosley's death was 'indeterminate' and 'unascertainable', adding that it 'was most likely attributable either to heatstroke (accidental) or non-identified pathological cause'. Mosley had presented BBC Radio 4's Just One Thing, and the BBC series Trust Me, I'm A Doctor, which looked at healthcare in Britain. He would regularly push his body during various programmes, and in a 2014 documentary he ingested tapeworms for six weeks. In a 2015 programme he made two black puddings out of his own blood to showcase its nutritional value. The BBC honoured the doctor-turned-science broadcaster with a day dedicated to him in July 2024, when presenters and audiences where encouraged to do 'just one thing' to improve their wellbeing. His wife Clare accepted the Hall of Fame Award at the British Podcast Awards on his behalf in September 2024.